vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and IDEAYA Biosciences, Inc. (IDYA). Click either name above to swap in a different company.
BALCHEM CORP is the larger business by last-quarter revenue ($263.6M vs $207.8M, roughly 1.3× IDEAYA Biosciences, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs 14.9%, a 42.5% gap on every dollar of revenue.
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
BCPC vs IDYA — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $263.6M | $207.8M |
| Net Profit | $39.2M | $119.2M |
| Gross Margin | 35.6% | — |
| Operating Margin | 19.8% | 52.2% |
| Net Margin | 14.9% | 57.4% |
| Revenue YoY | 9.8% | — |
| Net Profit YoY | 16.8% | 330.1% |
| EPS (diluted) | $1.21 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $263.6M | — | ||
| Q3 25 | $267.6M | $207.8M | ||
| Q2 25 | $255.5M | — | ||
| Q1 25 | $250.5M | — | ||
| Q4 24 | $240.0M | — | ||
| Q3 24 | $239.9M | $0 | ||
| Q2 24 | $234.1M | $0 | ||
| Q1 24 | $239.7M | $0 |
| Q4 25 | $39.2M | — | ||
| Q3 25 | $40.3M | $119.2M | ||
| Q2 25 | $38.3M | — | ||
| Q1 25 | $37.1M | — | ||
| Q4 24 | $33.6M | — | ||
| Q3 24 | $33.8M | $-51.8M | ||
| Q2 24 | $32.1M | $-52.8M | ||
| Q1 24 | $29.0M | $-39.6M |
| Q4 25 | 35.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 36.4% | — | ||
| Q1 25 | 35.2% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 35.6% | — | ||
| Q2 24 | 35.5% | — | ||
| Q1 24 | 34.0% | — |
| Q4 25 | 19.8% | — | ||
| Q3 25 | 20.4% | 52.2% | ||
| Q2 25 | 20.1% | — | ||
| Q1 25 | 20.4% | — | ||
| Q4 24 | 19.8% | — | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 19.6% | — | ||
| Q1 24 | 17.4% | — |
| Q4 25 | 14.9% | — | ||
| Q3 25 | 15.1% | 57.4% | ||
| Q2 25 | 15.0% | — | ||
| Q1 25 | 14.8% | — | ||
| Q4 24 | 14.0% | — | ||
| Q3 24 | 14.1% | — | ||
| Q2 24 | 13.7% | — | ||
| Q1 24 | 12.1% | — |
| Q4 25 | $1.21 | — | ||
| Q3 25 | $1.24 | $1.33 | ||
| Q2 25 | $1.17 | — | ||
| Q1 25 | $1.13 | — | ||
| Q4 24 | $1.03 | — | ||
| Q3 24 | $1.03 | $-0.60 | ||
| Q2 24 | $0.98 | $-0.68 | ||
| Q1 24 | $0.89 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $74.6M | $786.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $1.1B |
| Total Assets | $1.7B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.6M | — | ||
| Q3 25 | $65.1M | $786.9M | ||
| Q2 25 | $65.4M | — | ||
| Q1 25 | $49.9M | — | ||
| Q4 24 | $49.5M | — | ||
| Q3 24 | $73.7M | $920.0M | ||
| Q2 24 | $63.7M | $701.7M | ||
| Q1 24 | $60.3M | $698.8M |
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | $1.1B | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.2B | $1.2B | ||
| Q2 24 | $1.1B | $931.7M | ||
| Q1 24 | $1.1B | $935.3M |
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.7B | $1.2B | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.6B | $1.2B | ||
| Q2 24 | $1.6B | $973.7M | ||
| Q1 24 | $1.6B | $961.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $67.3M | $142.2M |
| Free Cash FlowOCF − Capex | — | $142.2M |
| FCF MarginFCF / Revenue | — | 68.4% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 1.72× | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | $13.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $67.3M | — | ||
| Q3 25 | $65.6M | $142.2M | ||
| Q2 25 | $47.3M | — | ||
| Q1 25 | $36.5M | — | ||
| Q4 24 | $52.3M | — | ||
| Q3 24 | $51.3M | $-49.2M | ||
| Q2 24 | $45.0M | $-32.9M | ||
| Q1 24 | $33.4M | $-43.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | $142.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-49.7M | ||
| Q2 24 | — | $-33.9M | ||
| Q1 24 | — | $-45.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | 68.4% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 1.72× | — | ||
| Q3 25 | 1.63× | 1.19× | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.40× | — | ||
| Q1 24 | 1.15× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCPC
| Human Nutrition And Health | $166.1M | 63% |
| Animal Nutrition And Health | $61.2M | 23% |
| Specialty Products | $34.8M | 13% |
IDYA
Segment breakdown not available.
